Skip to main content

12 Result(s)

within B Wassmann Remove this filter

and

  1. No Access

    Article

    Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

    Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relaps...

    H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, D Beelen… in Leukemia (2013)

  2. No Access

    Article

    Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

    Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with...

    H Pfeifer, T Lange, S Wystub, B Wassmann, J Maier, A Binckebanck, A Giagounidis… in Leukemia (2012)

  3. No Access

    Article

    New approaches to the treatment of adult acute lymphoblastic leukaemia

    In this review we describe general therapeutic options for adult patients with acute lymphoblastic leukaemia and focus on specific new treatment strategies. Current novel approaches include monoclonal antibodi...

    Nicola Gökbuget MD, B. Wassmann in memo - Magazine of European Medical Oncology (2009)

  4. No Access

    Article

    A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

    B. Wassmann, N. Gökbuget, U. J. Scheuring, A. Binckebanck… in Annals of Hematology (2003)

  5. No Access

    Article

    Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

    Imatinib has marked antileukemic activity in advanced Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), but secondary resistance develops rapidly, reflecting the limitations of single-agent ...

    B Wassmann, U Scheuring, H Pfeifer, A Binckebanck, A Käbisch, M Lübbert… in Leukemia (2003)

  6. No Access

    Article

    Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

    We studied 128 patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (SCT). Disease at the time of treatment with Imatinib was in chronic phase (CP) in 51 patients, ...

    E Olavarria, O G Ottmann, M Deininger, R E Clark, G Bandini, J Byrne, J Lipton… in Leukemia (2003)

  7. No Access

    Article

    Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

    Patients with refractory or relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) rarely have prolonged responses to salvage therapy, including imatinib, resulting in a short opportun...

    U J Scheuring, H Pfeifer, B Wassmann, P Brück, B Gehrke, E K Petershofen… in Leukemia (2003)

  8. No Access

    Article

    Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

    We report the response to the ABL kinase inhibitor imatinib mesylate (STI571) in a patient with chronic myeloid leukemia (CML) who relapsed twice after dose-reduced allogeneic stem cell transplantation (alloSC...

    B Wassmann, U Scheuring, C Thiede, H Pfeifer, M Bornhäuser… in Bone Marrow Transplantation (2003)

  9. No Access

    Article

    Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

    Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 cons...

    B Wassmann, H Pfeifer, U Scheuring, SA Klein, N Gökbuget, A Binckebanck… in Leukemia (2002)

  10. No Access

    Article

    Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

    We describe the clinical activity of the ABL kinase inhibitor STI571 in a patient with accelerated phase of chronic myeloid leukemia (CML) relapsing after a second allogeneic BMT and with minimal levels of don...

    B Wassmann, SA Klein, U Scheuring, H Pfeifer, H Martin… in Bone Marrow Transplantation (2001)

  11. No Access

    Article

    Recombinant human granulocyte and granulocyte–macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells

    The availability of hematopoietic growth factors has greatly facilitated the mobilization and collection of peripheral blood stem cells (PBSC). It was the aim of this double-blind study to compare the PBSC-mob...

    S Hohaus, H Martin, B Wassmann, G Egerer, U Haus, L Färber… in Bone Marrow Transplantation (1998)

  12. No Access

    Article

    Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

     The toxicity and outcome after high-dose ara-C/daunorubicin (HDara-C/DNR) consolidation therapy in de novo AML was compared in 11 patients who received an idarubicin-containing induction therapy (IDA; from Ju...

    G. Seipelt, W.-K. Hofmann, H. Martin, B. Wassmann, A. Boehme… in Annals of Hematology (1998)